What is Euclises Pharmaceuticals?
Euclises Pharmaceuticals, Inc. is a biopharmaceutical firm focused on developing innovative cyclooxygenase-2 (COX-2) inhibitors, branded as EuclicoxibsTM, for oncological applications. In collaboration with its development partner, the Guangzhou Institute of Biomedicine and Health (GIBH), Euclises has identified a clinical development candidate, ECP-1014. The company is currently undertaking studies to prepare for human clinical trials. Headquartered at BioGenerator Labs within CORTEX, Euclises has received backing from a notable group of investors, including Cultivation Capital, BioGenerator, Missouri Technology Corporation, the iSelect Fund, and the St. Louis Arch Angels.
How much funding has Euclises Pharmaceuticals raised?
Euclises Pharmaceuticals has raised a total of $3.2M across 3 funding rounds:
Private Equity
$174K
Private Equity
$1.9M
Private Equity
$1.2M
Private Equity (2012): $174K with participation from St Louis Arch Angels
Private Equity (2013): $1.9M led by Cultivation Capital, BioGenerator, and St Louis Arch Angels
Private Equity (2015): $1.2M, investors not publicly disclosed
Key Investors in Euclises Pharmaceuticals
Cultivation Capital
Cultivation Capital is a venture capital firm specializing in early-stage companies across life sciences, software, and agriculture, providing capital and network support for hyper-growth from Seed through Series B.
BioGenerator
BioGenerator is an organization based in St. Louis, Missouri, dedicated to creating and growing innovative companies through investment via BioGenerator Ventures and startup support services through BioGenerator Labs.
St Louis Arch Angels
The St. Louis Arch Angels is an angel investor network focused on funding early-stage businesses in the St. Louis region, with a history of significant investment in local startups to foster economic growth.
What's next for Euclises Pharmaceuticals?
The recent major strategic investment signifies a critical phase for Euclises Pharmaceuticals, likely enabling the company to advance its lead candidate, ECP-1014, into human clinical trials. This capital infusion is pivotal for navigating the rigorous and expensive process of drug development, from preclinical studies to regulatory submissions. The company's focus on COX-2 inhibitors for cancer treatment positions it within a significant therapeutic area, and further investment will be crucial for scaling operations, expanding its research pipeline, and potentially forging new partnerships to accelerate market entry.
See full Euclises Pharmaceuticals company page
